Building a Bridge Between the Mechanism of EBV Reactivation and the Treatment of EBV‐Associated Cancers
Authors:
- 27 January 2025
- journal article
- review article
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (2) , e70192
Abstract
Epstein‐Barr virus (EBV) infection is closely associated with the development of various tumors such as lymphomas and epithelial cancers. EBV has a discrete life cycle with latency and lytic phases. In recent years, significant progress has been made in the understanding of the mechanism underlying the transition of EBV from latency to lytic replication. Multiple new lytic activation factors have been emerged and promoted our understanding of this field. In addition, we have comprehensively presented the existing therapeutic strategies and their relationship to the mechanism underlying the transition of EBV from latency to lytic replication in this review, such as lytic induction therapy and drugs to prevent EBV from entering the lytic phase fully utilize the EBV reactivation mechanisms. This year marks the 60th anniversary of the discovery of EBV, and building a bridge between the mechanism of EBV reactivation and the treatment may help us to design new approaches for treating EBV‐associated diseases.Keywords
Funding Information
- National Natural Science Foundation of China
- Education Department of Hunan Province
This publication has 133 references indexed in Scilit:
- Epstein‐Barr virus‐driven metabolic alterations contribute to the viral lytic reactivation and tumor progression in nasopharyngeal carcinomaJournal of Medical Virology, 2024
- IFIT3 inhibits Epstein‐Barr virus reactivation via upregulating innate immunityJournal of Medical Virology, 2023
- A bacterial genotoxin causes virus reactivation and genomic instability in Epstein–Barr virus infected epithelial cells pointing to a role of co‐infection in viral oncogenesisInternational Journal of Cancer, 2018
- The role of oxidative stress in EBV lytic reactivation, radioresistance and the potential preventive and therapeutic implicationsInternational Journal of Cancer, 2017
- Emodin: A Review of its Pharmacology, Toxicity and PharmacokineticsPhytotherapy Research, 2016
- Activation of lytic cycle of Epstein‐Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinomaInternational Journal of Cancer, 2012
- Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein‐Barr virus‐positive epithelial malignancies and mediates enhanced cell deathInternational Journal of Cancer, 2009
- Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cellsInternational Journal of Cancer, 2009
- The chemopreventive compound curcumin is an efficient inhibitor of Epstein‐Barr virus BZLF1 transcription in Raji DR‐LUC cells*Molecular Carcinogenesis, 2002
- Induction of Epstein‐Barr virus in B‐lymphoblastoid cells by human immunodeficiency virus type 1International Journal of Cancer, 1989